259807-97-1

Basic information

• Product Name: 3-METHYL-2-(TRIBUTYLSTANNYL)PYRIDINE
• Synonyms: 3-METHYL-2-(TRIBUTYLSTANNYL)PYRIDINE;3-Methyl-2-(tri-n-butylstannyl)pyridine, 96%;(3-Methylpyridin-2-yl)tributylstannane, 2-(Tributylstannyl)-3-picoline;2-(Tributylstannyl)-3-Methylpyridine;tributyl-(3-methylpyridin-2-yl)stannane
• CAS NO: 259807-97-1
• Molecular Formula: C₁₈H₃₃NSn
• Molecular Weight: 382.17
• Product Categories: Stannanes
• Mol File: 259807-97-1.mol

Chemical Properties

• Boiling Point: 396.76°C at 760 mmHg
• Flash Point: 193.754°C
• Appearance: /
• Vapor Pressure: 0mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Water Solubility: Sparingly soluble in water.
• CAS DataBase Reference: 3-METHYL-2-(TRIBUTYLSTANNYL)PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-METHYL-2-(TRIBUTYLSTANNYL)PYRIDINE(259807-97-1)
• EPA Substance Registry System: 3-METHYL-2-(TRIBUTYLSTANNYL)PYRIDINE(259807-97-1)

Safety Data

• Hazard Codes: T
• HazardClass: 6.1
• Hazardous Substances Data: 259807-97-1(Hazardous Substances Data)

Usage

Uses

3-Methyl-2-(tri-n-butylstannyl)pyridine is used as pharmaceutical intermediate.

InChI:InChI=1/C6H6N.3C4H9.Sn/c1-6-3-2-4-7-5-6;3*1-3-4-2;/h2-4H,1H3;3*1,3-4H2,2H3;/rC18H33NSn/c1-5-8-14-20(15-9-6-2,16-10-7-3)18-17(4)12-11-13-19-18/h11-13H,5-10,14-16H2,1-4H3

Upstream product

• 1461-22-9 tributyltin chloride 
• 3430-17-9 2-bromo-3-picoline 
• 2369-18-8 2-fluoro-3-methylpyridine 
• 17955-46-3 trimethylsilyltributyltin 

Relevant articles and documents

Illuminating Stannylation

We have developed photoboosted stannylation reactions of terminal alkynes (linear-selective hydrostannylation) and fluoroarenes (defluorostannylation), in which the stannyl anion is photoexcited to an excited triplet (T1) stannyl diradical species. This u

SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS

The present invention is directed to compounds of Formula I: wherein ring A is phenyl, naphihalenyl, pyridyl, quinolinyl, isoquinolinyl, imidazopyridyl, furanyi, tlisazolyl, isoxazolvl, pyrazolyl, imidazothiazolyi, benzimidazolyl, or indazolyi; R1 is H, alky], aikoxy, hydroxyalkylene, OH, halo, phenyl, triazolyl, oxazolyl, isoxazofyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazmyl, piperazinyl, pyrazolyl, oxadiazolvl, pyrrolidinyl, thiophenyi, morpholinyl, or dialkyiamino; R2 is H, alkyl, aikoxy, hydroxyalkylene, or halo; Z is NH, N-alkyl, or O; R5 is pyridyl, pyrimidinyl, pyrazinyl, pyridazmyl, qumazolinyi, quinoxalinyl, pyrazolyl, benzoxazolyl, imidazopyrazinyl, triazolopyrazinyl, optionally substituted with a one or two substituents independently selected from the group consisting of alkyl, aikoxy, or halo; and n is 0 or 1, Methods of making the compounds of Formula 1 are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.

Acid secretion inhibitor

The present invention provides a compound having a superior acid secretion inhibitory effect and showing an antiulcer activity and the like. The present invention provides a compound represented by the formula (I) wherein R1 is a nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle, the nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle optionally has substituent(s), R2 is an optionally substituted C6-14 aryl group, an optionally substituted thienyl group or an optionally substituted pyridyl group, R3 and R4 are each a hydrogen atom, or one of R3 and R4 is a hydrogen atom and the other is an optionally substituted lower alkyl group, an acyl group, a halogen atom, a cyano group or a nitro group, and R5 is an alkyl group or a salt thereof.

NOVEL SULFONYL DERIVATIVES

Sulfonyl derivatives represented by the following general formula (I): Q1-Q2-T1-Q3-SO2-QA and drugs containing the same (wherein Q1 is an optionally substituted, saturated or unsaturated, five- or six-membered cyclic hydrocarbon group, a five- or six-membered heterocyclic group, or the like; Q2 is a single band, oxygen, sulfur, C1-C6 alkylene or the like; QA is optionally substituted arylalkenyl, heteroarylalkenyl or the like; and T1 is carbonyl or the like). These compounds have potent FXa-inhibitory effects and promptly exert satisfactory and persistent antithrombotic effects through oral administration, thus being useful as anticoagulant agents little accompanied with side effects.